# InMed Pharmaceuticals Q3 2025 Earnings Analysis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/inmed-pharmaceuticals-q3-2025-earnings-analysis/ > **Published:** 2026-05-25T00:16:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:48-04:00 > **Clinical Summary:** Review of InMed Pharmaceuticals Q3 2025 earnings highlights financial losses and challenges in cannabinoid therapeutics development. --- In the Mix — Last 24 HoursMay 25, 2026. 1 article reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #17.5 [InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock Declines – Newser](http://www.newser.com/expert-time/InMed-Pharmaceuticals-Q3-2025-Earnings-Continued-Losses-as-Stock-Declines-22-5358) This article details InMed Pharmaceuticals’ financial losses in Q3 2025, which may be of interest to clinicians tracking the economic landscape of [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) and development. [Read more →](http://www.newser.com/expert-time/InMed-Pharmaceuticals-Q3-2025-Earnings-Continued-Losses-as-Stock-Declines-22-5358) Digest-Level Clinical Commentary Dr. Caplan’s Take The reported losses at InMed Pharmaceuticals underscore a sobering reality in cannabinoid therapeutics: translating [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) into FDA-approved, revenue-generating medications remains extraordinarily difficult, which means clinicians like myself cannot yet rely on standardized pharmaceutical cannabinoid products for most indications. This financial struggle suggests that the burden of proof for cannabinoid efficacy in clinical practice will continue to rest on real-world evidence and patient outcomes rather than on major pharmaceutical infrastructure, keeping us in a transitional period where evidence quality remains inconsistent across conditions. For my practice, this reinforces the importance of maintaining rigorous patient selection, robust documentation, and realistic expectations about what cannabis can accomplish until the pharmaceutical pipeline produces drugs with the clinical validation we typically demand. Clinical Perspective InMed Pharmaceuticals’ continued operating losses and lack of revenue generation highlight the substantial development timeline and financial challenges inherent in bringing cannabinoid-based therapeutics through [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to market approval. The company’s financial trajectory underscores the reality that cannabinoid [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) requires years of rigorous scientific validation before generating revenue, a path that differs meaningfully from the established cannabis industry. Clinicians monitoring this space should recognize that while [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) shows promise in specific therapeutic areas, the commercial viability of pharmaceutical cannabinoid products remains uncertain and dependent on successful trial completion and regulatory approval. Cannabis IndustryFinancial PerformancePharmaceutical DevelopmentBiotech CompaniesMarket AnalysisRegulatory News 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+In+the+Mix+%E2%80%94+May+25%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+In+the+Mix+%E2%80%94+May+25%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 3 More Articles — May 24, 2026](https://cedclinic.com/cannabinoid-pharmaceutical-financial-challenges-2026/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [In the Mix: 4 More Articles — March 17, 2026](https://cedclinic.com/4-cannabis-articles-clinical-relevance-march-17-2026/) Explore additional articles covering recent developments in [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) and clinical updates. [Read More](https://cedclinic.com/4-cannabis-articles-clinical-relevance-march-17-2026/) [The Best CBD for Immune Support and Daily Resilience in 2026](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Discover top [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) and their potential benefits for immune health and resilience in 2026. [Learn More](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) [MMJ ET AL Prepares Appeal CMS Hemp Program](https://cedclinic.com/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a/) Insights into regulatory challenges and appeals related to hemp programs affecting cannabinoid companies. [Explore Details](https://cedclinic.com/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).